A phase III study of neratinib in HER2-positive, locally advanced or metastatic breast cancer previously treated with a trastuzumab (Herceptin)-based regimen.
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2012
At a glance
- Drugs Neratinib (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 14 Aug 2012 Planned initiation date changed from 1 June 2012 to 1 Dec 2012.
- 07 Oct 2011 New trial record